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Semi-synthetic vNAR libraries 
screened against therapeutic 
antibodies primarily deliver anti-
idiotypic binders
Doreen Könning1,2, Laura Rhiel3, Martin Empting  5, Julius Grzeschik1,2, Carolin Sellmann4, 
Christian Schröter3, Stefan Zielonka4, Stephan Dickgießer3, Thomas Pirzer1, Desislava 
Yanakieva1,2, Stefan Becker4 & Harald Kolmar  1,2
Anti-idiotypic binders which specifically recognize the variable region of monoclonal antibodies have 
proven to be robust tools for pharmacokinetic studies of antibody therapeutics and for the development 
of cancer vaccines. In the present investigation, we focused on the identification of anti-idiotypic, shark-
derived IgNAR antibody variable domains (vNARs) targeting the therapeutic antibodies matuzumab 
and cetuximab for the purpose of developing specific capturing ligands. Using yeast surface display 
and semi-synthetic, CDR3-randomized libraries, we identified several highly specific binders targeting 
both therapeutic antibodies in their corresponding variable region, without applying any counter 
selections during screening. Importantly, anti-idiotypic vNAR binders were not cross-reactive towards 
cetuximab or matuzumab, respectively, and comprised good target recognition in the presence of 
human and mouse serum. When coupled to magnetic beads, anti-idiotypic vNAR variants could be used 
as efficient capturing tools. Moreover, a two-step procedure involving vNAR-functionalized beads was 
employed for the enrichment of potentially bispecific cetuximab × matuzumab antibody constructs. 
In conclusion, semi-synthetic and CDR3-randomized vNAR libraries in combination with yeast 
display enable the fast and facile identification of anti-idiotypic vNAR domains targeting monoclonal 
antibodies primarily in an anti-idiotypic manner.
Over the past decades, monoclonal antibodies have gained preeminent importance in the treatment of cancer as 
well as inflammatory and autoimmune diseases1, 2. With more than 30 antibody therapeutics being marketed and 
over 50 in late stage clinical trials, the market is growing more rapidly than ever2–5. This development, however, 
requires a reliable toolbox for the characterization and monitoring of these therapeutic entities as they progress 
into the clinic. While for some characterizations, such as the assessment of serum stability, the antigen can be 
employed as a capturing ligand, this approach may be limited when the antigen is not easily available, expensive 
or poses a safety threat6–8. The monitoring of a therapeutic antibody in patient serum can be particularly chal-
lenging and requires a molecule that exhibits excellent target recognition in the presence of excess IgG competitor 
molecules. In this case, anti-idiotypic antibodies which specifically recognize an idiotope located in the variable 
regions of a therapeutic antibody can be employed. Their high specificity for the unique antigenic determinants 
of the therapeutic antibody enable them to distinguish between their target and unrelated antibody variants. 
Such anti-idiotypic antibodies are of great importance in the assessment of the pharmacokinetic properties of a 
therapeutic antibody and can also be employed as a standard in the identification of anti-drug responses in order 
to analyze potential immunogenicity issues9. In addition to their utilization in various immunoassay formats, 
anti-idiotypic antibodies have been employed for the immunoaffinity enrichment of therapeutic antibodies, for 
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mass spectrometric analyses10, 11, for the purification of bispecific antibodies12 and as cancer vaccines13, 14. With 
regard to their employment as cancer vaccines, anti-idiotypic antibodies which represent an ‘internal image’ of the 
actual antigen can be used for immunizations. The immune response that is elicited comprises anti-anti-idiotypic 
antibodies which in turn exhibit properties similar to those of the actual therapeutic antibody15, 16. This approach 
is especially feasible when self-antigens which are naturally non-immunogenic or even of a non-proteic nature 
are being addressed13.
Many anti-idiotypic antibody and non-antibody molecules have been developed for this purpose. Examples 
include, among others, anti-idiotypic monobodies, scFvs, peptides or nanobodies14, 17–21. In the present investi-
gation, we describe the identification of anti-idiotypic, shark-derived antibody domains targeting monoclonal 
antibodies. In comparison to conventional antibodies derived from mammals, cartilaginous fish (sharks, rays 
and skates) possess a unique form of heavy-chain only antibodies, termed immunoglobulin new antigen recep-
tor or IgNAR22. Each heavy chain of this unique isotype possesses overall five constant domains followed by 
the variable domain (vNAR) that mediates antigen binding22. The absence of a light chain partner contributes 
to the high water solubility of vNAR domains since the hydrophobic VH-VL interface of a conventional anti-
body is replaced by polar and charged amino acid residues23–25. Overall, vNAR domains possess two (CDR1 
and CDR3) instead of three CDR loops, which is attributed to the structural depletion of a β-sheet24. However, 
the lack of a CDR2 binding site is at least in part compensated by the elongated CDR3 region that mediates 
the major part of antigen-binding (Fig. 1a). Additionally, their small size of approximately 11–12 kDa renders 
vNARs the smallest antibody-like antigen-binding domains known to date. Moreover, their small size and elon-
gated CDR3 binding sites enable them to interact with structurally demanding, cleft-like epitopes which are often 
Figure 1. Screening of semi-synthetic, yeast-displayed vNAR libraries towards matuzumab and cetuximab. 
(a) Structural depiction of an IgNAR variable domain (vNAR). The CDR1 and CDR3 loops are highlighted in 
blue and purple, respectively. For the generation of semi-synthetic vNAR libraries in the scope of this work, 
only the CDR3 regions were randomized. The structure was modified from PDB identifier 4HGK using UCSF 
Chimera49. (b) Schematic depiction of the yeast surface display setup employed for the semi-synthetic vNAR 
libraries. Randomized vNAR domains are fused to the C-terminus of Aga2p. Full-length surface presentation 
is verified upon staining of the C-terminal myc tag. (c) Structural depiction of cetuximab and matuzumab Fab 
fragments targeting domain III of the extracellular portion of EGFR. It is apparent from the illustration, that 
both antibodies target neighbouring epitopes on EGFR. All structures were modified from PDB identifiers 
1YY9 (cetuximab and EGFR) or 3C09 (matuzumab and EGFR domain III) using UCSF chimera49. (d) Dot plot 
diagrams depicting cells after the fourth or fifth sorting round towards cetuximab or matuzumab, respectively. 
Negative controls were incubated with secondary antibodies only (upper and lower left).
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intractable for conventional antibodies26–29. The aforementioned characteristics as well as their high physico-
chemical stability render vNAR domains ideal for biomedical and biotechnological research and have led to the 
isolation of various vNAR candidates binding therapeutically relevant targets such as TNFα30, EpCAM31 or the 
malarial AMA protein28. In addition, it has been demonstrated that these domains can be engineered towards 
pH-sensitive target binding, opening up new avenues for the development of affinity ligands for tailor-made 
chromatographic applications32. Owing to these striking characteristics, we suggest that vNAR domains could be 
predisposed for the targeting of antibody variable regions. Their elongated CDR3 loops can potentially penetrate 
these regions and address recessed interspaces. Moreover, their high stability should enable their utilization in 
various immunoassay formats and under a variety of different conditions. Therefore, we wanted to investigate 
whether anti-idiotypic vNAR variants towards therapeutic antibodies could be isolated. In contrast to the com-
mon approaches described in literature, which have almost exclusively relied on phage display as high-throughput 
screening platform, we employed yeast surface display for the identification of anti-idiotypic binders (Fig. 1b)33. 
This bears the inherent advantage of simultaneous on-line and real-time analysis during fluorescence-activated 
cell sorting (FACS)34. In addition, the approach described in the present investigation relies on semi-synthetic 
instead of immune libraries, completely obviating the need for animal immunizations. This is an advantageous 
feature, especially when compared to the generation of camelid-derived heavy chain antibodies, which commonly 
involves the immunization of llamas or camelids12, 14.
In order to test the robustness of the presented approach, we chose cetuximab and matuzumab as target anti-
bodies35–38. Both antibodies are directed towards the epidermal growth factor receptor (EGFR) and even engage 
neighbouring epitopes on domain III of its extracellular portion (Fig. 1c). While cetuximab has been approved by 
the FDA for the treatment of several cancer types, the clinical development of matuzumab has not been pursued35. 
In 2010, Hartmann and colleagues described the isolation of anti-idiotypic peptides targeting matuzumab and 
cetuximab from peptide phage libraries15. However, the selected library candidates were cross-reactive, compris-
ing micromolar affinities for both target antibodies. Herein, we show that semi-synthetic, yeast-displayed vNAR 
libraries allow for the facile identification of highly specific and non-cross-reactive anti-idiotypic variants towards 
cetuximab and matuzumab. When immobilized on magnetic beads, these anti-idiotypic domains demonstrated 
their potential as capturing ligands in the presence of mouse serum as well for the immunoaffinity enrichment of 
bispecific cetuximab × matuzumab constructs.
Results
The isolation of anti-idiotypic vNARs from semi-synthetic yeast libraries does not require coun-
ter selections. We generated overall four yeast-displayed vNAR libraries from naïve bamboo shark scaffolds 
as described previously31. The CDR3 binding site, which mediates the major part of the antibody-antigen inter-
action, was synthetically randomized using PCR and trimer-based oligonucleotide mixtures encoding for 12, 14, 
16 or 18 amino acids, respectively, thereby extending the average length of 12 amino acids naturally found in the 
bamboo shark31. Randomized vNAR sequences were subjected to a second PCR, resulting in the assembly of the 
finalized inserts that comprised gap repair overhangs for homologous recombination in yeast. The generation 
of the four yeast libraries was performed using a high-yield transformation protocol39 and yielded a potential 
diversity of 3 × 109 transformants altogether. After cultivation of the yeast libraries and induction of vNAR-ex-
pression in galactose-containing medium, surface presentation was detected upon fluorescent labelling of the 
C-terminal myc epitope tag (Fig. 1d). Overall, 35% of the analyzed cell population showed myc tag and, conse-
quently, full-length expression of a vNAR domain. In order to analyze the library content in terms of binding to 
cetuximab, we performed target stainings with a 1 µM concentration of the antibody. Detection was performed 
using anti-human Fc-specific labelling antibodies. After four rounds of screening without the application of any 
counter selections, a significant portion of the yeast cell population showed strong binding to cetuximab (Fig. 1d). 
Subsequently, we analyzed the outcome of the fourth sorting round in terms of its sequence diversity. Overall, 
ten single clones were analyzed comprising only three different vNAR sequences. As one of the single clones 
possessed a CDR3 that was mainly composed of aromatic residues, potentially indicating non-specific interac-
tions with the antibody target, we chose the two remaining anti-cetuximab vNARs AC-VNAR1 and AC-VNAR2 
for further characterizations. Both variants were subsequently scrutinized in terms of anti-idiotypic binding 
towards cetuximab. As depicted in Fig. 2a, the single clones showed significant binding to 100 nM cetuximab, 
but no binding to 10 µM matuzumab. Also, no binding to other unrelated monoclonal antibodies was observable 
(Supplementary Figs 2 and 3). In addition, competition experiments involving an excess of a therapeutically uti-
lized human IgG mixture (Gamunex®) were conducted. Both vNAR single clones were able to specifically target 
biotinylated cetuximab at a concentration of 10 nM and in the presence of 50 µM of Gamunex® (Supplementary 
Figs 2 and 3). In contrast to a positive control, that was performed without the addition of competitor, the binding 
capabilities of both clones were not impaired.
The screening procedure was repeated for the identification of vNAR library candidates that specifically 
engage matuzumab instead of cetuximab. Overall, five rounds of selection were performed in this case, resulting 
in a population that comprised binders with high affinity for matuzumab even in the presence of excess cetuximab 
(Fig. 1d and Supplementary Fig. S4). Out of overall ten single clones which were sent out for sequencing analyses, 
two unique sequences were obtained (Supplementary Fig. S1). These two single clones, termed AM-VNAR1 and 
AM-VNAR2, were then further characterized in terms of anti-idiotypic binding to matuzumab. As has been 
observed for the identified cetuximab binders, both clones showed distinct recognition of matuzumab but no 
binding to excess cetuximab (Fig. 2b) or other unrelated monoclonal antibodies (Supplementary Figs 5 and 6), 
indicating high specificity and anti-idiotypic binding. Competition experiments which involved the incubation 
of both single clones with 50 nM biotinylated matuzumab in the presence of 50 µM Gamunex® further empha-
sized their high specificity, as no competition and, therefore, no decrease in the binding signal could be observed 
(Supplementary Figs 5 and 6).
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Reformatted anti-idiotypic vNARs show high affinity and specificity. Single clones AC-VNAR1, 
AC-VNAR2, AM-VNAR1 and AM-VNAR2 were subcloned into a mammalian expression vector that enabled 
the expression of each vNAR as a fusion to a human IgG1 Fc region. Expi293FTM cells were transiently transfected 
and the produced proteins were purified from the culture supernatants after five days using Protein A spin col-
umns. The purity of all four constructs as Fc fusions was determined by analytical size exclusion chromatography 
and was higher than 93% (Supplementary Fig. S7). We then determined the affinities of the reformatted, bivalent 
vNAR-Fc constructs using Bio-Layer Interferometry (BLI). All four variants displayed affinities in the low nano-
molar range, with AM-VNAR1 exhibiting a KD value of 900 pM (Table 1, Supplementary Fig. S8). These bivalent 
affinities are most likely higher than those of the solitary vNAR domains, however, we propose, that they can 
potentially be engineered towards even higher affinities after conducting an incremental affinity maturation that 
involves randomization of the adjacent CDR1 loop (Fig. 1a)31. The specificity of all anti-idiotypic variants was fur-
ther assessed in an ELISA format, as this type of immunoassay is the one most commonly used when characteriz-
ing a therapeutic antibody in the first place. Therefore, all four vNAR variants were coated onto microtiter plates 
at 4 °C over night. After a blocking step, incubations with cetuximab, matuzumab as well as several unrelated 
antibodies and Gamunex® were performed. Captured antibodies were detected using an anti-Fab-HRP conju-
gated antibody that interacts with the Fab region of the monoclonal antibodies but not with the vNAR-Fc fusion 
proteins. As depicted in Fig. 2c, specific binding to cetuximab is observable for single clones AC-VNAR1 and 
AC-VNAR2 (upper panel). Likewise, single clones AM-VNAR1 and AM-VNAR2 specifically engage matuzumab 
Figure 2. Single clones derived from rounds four and five towards cetuximab and matuzumab were tested in 
terms of target specificity on yeast and in an ELISA setup after recombinant expression. (a) Dot plot diagrams 
depicting yeast cells that display single clones AC-VNAR1 and AC-VNAR2 and were incubated with secondary 
labelling reagents (negative control), 100 nM cetuximab or 10 µM matuzumab. (b) Dot plot diagrams depicting 
yeast cells that present single clones AM-VNAR1 and AM-VNAR2 on their surface and were incubated with 
secondary labelling reagents (negative control), 100 nM matuzumab or 10 µM cetuximab. Full-length surface 
display was verified upon addressing the C-terminal myc tag. (c) Recombinantly expressed anti-idiotypic vNAR 
variants were coated into 96-well microtiter plates and incubated with cetuximab or matuzumab as well as 
other unrelated monoclonal antibodies and an IgG1 mixture (Gamunex®). Detection of bound antibodies was 
performed using a Fab-specific detection antibody conjugated to horseradish peroxidase. Experiments were 
performed in duplicates. Standard deviations are indicated in each diagram. In case of AC-VNAR1 and AM-
VNAR2, 1000 nM of each antibody were employed. In case of AC-VNAR2 and AM-VNAR1, 500 nM of each 
antibody were utilized.
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and exhibit only minor interactions with other, unrelated antibodies (Fig. 2c, lower panel). These minor inter-
actions can most likely be attributed to the slightly increased percentage of aggregates observed for these vNAR 
variants during size exclusion chromatography analysis (Supplementary Fig. S7).
Anti-idiotypic vNARs selectively detect their target antibody in the presence of human 
serum. As serum stability assays as well as the quantification of a therapeutic antibody in patient serum 
are essential during the preclinical and clinical development of an antibody biologic, we next assessed whether 
anti-idiotypic vNARs were able to engage their biotinylated targets in the presence of 10% human serum. 
Therefore, decreasing concentrations of each biotinylated target antibody in the presence or absence of human 
serum were incubated with vNAR-coated wells. As depicted in Fig. 3a and b, only vNAR domains AC-VNAR2 
and AM-VNAR1 were able to specifically recognize the biotinylated target antibody in the presence of human 
serum, whereas variants AC-VNAR1 and AM-VNAR2 showed decreased target binding when serum was present 
during the incubations. This indicates unspecific interactions with proteins present in human serum which can 
engage AC-VNAR1 and AM-VNAR2, hampering binding to cetuximab or matuzumab. As a consequence, only 
anti-idiotypic vNARs AC-VNAR2 and AM-VNAR1 were suited for further capturing assays in serum.
Anti-idiotypic vNARs solely engage correctly assembled antibody paratopes. In order to inves-
tigate whether the idiotope that is being recognized by the anti-idiotypic vNAR variants on each target antibody 
is located on the heavy chain, the light chain or at the interface of both chains, we performed idiotype binding 
analyses. For this purpose, we co-transfected Expi293FTM cells with plasmids encoding for the matuzumab heavy 
vNAR variant   KD (nM) kon (M−1 s−1) kdis (s−1)
AC-VNAR1 8.6 ± 0.1 2.6 × 105 ± 3.2 × 103 2.3 × 10−3 ± 1.1 × 10−5
AC-VNAR2 3.7 ± 0.098 1.7 × 106 ± 4.2 × 101 6.5 × 10−3 ± 5.5 × 10−5
AM-VNAR1 0.9 ± 0.027 4.0 × 104 ± 9.5 × 101 4.0 × 10−5 ± 1.1 × 10−6
AM-VNAR2 9.1 ± 0.071 7.2 × 104 ± 4.4 × 102 6.5 × 10−4 ± 3.2 × 10−6
Table 1. Kinetic parameters of anti-idiotypic vNARs as Fc fusion proteins. Values were determined using Bio-
Layer Interferometry.
Figure 3. Results of the serum ELISA experiments encompassing anti-idiotypic vNARs. (a) Anti-idiotypic 
vNAR variants AC-VNAR1 and 2 were coated into 96-well microtiter plates. After a blocking step, wells were 
incubated with serial dilutions of biotinylated cetuximab in the presence (light gray) or absence (dark gray) 
of 10% human serum. Experiments were performed in duplicates, standard deviations are indicated in each 
diagram. (b) Anti-idiotypic vNAR variants AM-VNAR1 and 2 were coated into 96-well microtiter plates. After 
a blocking step, wells were incubated with serial dilutions of biotinylated matuzumab in the presence or absence 
of 10% human serum. Experiments were performed in duplicates, standard deviations are indicated in each 
diagram.
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chain together with the cetuximab light chain (Matuz HC/Cetux LC) and vice versa (Cetux HC/Matuz LC). The 
culture supernatants were harvested after five days of production and purified using Protein A spin columns. 
Supplementary Fig. S9 depicts an SDS-PAGE of the mispaired variants after purification. Each lane contains 
protein bands which correspond to the heavy and light chain, verifying the correct assembly of these constructs. 
It is also apparent from the SDS-PAGE, that the cetuximab and matuzumab light chains differ slightly in size. 
Ultimately, matuzumab and cetuximab as well as the mispaired variants were immobilized on BLI sensor tips 
and subsequently transferred into wells containing the anti-idiotypic vNARs. As depicted in Fig. 4, only the 
complete antibody molecules consisting of correctly paired heavy and light chains were recognized. These results 
clearly demonstrate that the identified anti-idiotypic vNARs are paratope-specific for their corresponding target 
antibody and that both, the heavy and the light chain variable region are engaged in binding. It is interesting to 
note that solely paratope-specific binders rather than variants which engage the antibody constant regions were 
obtained, although no selection pressure was applied during the yeast display screenings12.
Affinity capture of therapeutic antibodies from 5% mouse serum using magnetic beads. In 
order to investigate the capturing abilities of anti-idiotypic vNARs AC-VNAR2 and AM-VNAR1, we biotinylated 
both variants and incubated them with streptavidin-functionalized magnetic beads. After removal of unbound 
and unspecifically bound vNARs upon stripping of the beads with 0.1 M glycine buffer at pH 3, we incubated 
them with 10 µg (440 nM) of the corresponding therapeutic antibody in the presence of 5% mouse serum in PBS. 
Subsequently, the beads were washed several times with PBS and vNAR-bound antibodies were eluted using 
0.1 M glycine buffer at pH 3. The purification procedure was illustrated on a western blot membrane that was 
stained with Ponceau S directly after the proteins were transferred from the SDS-PAGE (Fig. 5, upper and lower 
left). Ponceau S interacts with positively charged amine groups, thereby staining all the protein that has success-
fully been transferred to the western blot membrane. As depicted in Fig. 5, both capturing experiments encom-
passing AC-VNAR2 and AM-VNAR1 functionalized magnetic beads contain a high portion of serum proteins 
in both, the sample prior to application to the beads and in the flowthrough after bead incubation. The eluates of 
both experiments, however, comprise distinct bands corresponding to an IgG heavy and light chain with sizes of 
approximately 50 and 25 kDa (Fig. 5, upper and lower left). In order to prove that these bands correspond to the 
human therapeutic antibodies cetuximab and matuzumab instead of unspecific mouse IgG, we washed away the 
Ponceau S and specifically detected the human Fc part of both antibodies using an anti-human Fc alkaline phos-
phatase conjugate (Fig. 5, upper and lower right). Both, the samples prior to application to the beads and the elu-
ates contain either cetuximab or matuzumab as indicated by a specific band that is visible after staining with the 
anti-human Fc conjugate. These results emphasize the potential of the identified anti-idiotypic vNARs as captur-
ing agents for therapeutic antibodies in complex serum samples40. Applications for such vNAR-coated magnetic 
beads include, among others, the quantification of therapeutic antibodies in mass-spec based immuno-MRM 
assays41.
Immunoaffinity enrichment of bispecific antibodies using anti-idiotypic vNARs. Analogous to 
the work recently published by Godar and colleagues, we wanted to investigate whether anti-idiotypic vNARs 
were able to identify bispecific antibodies from a heterogeneous mixture12. In this manner, a two-step purification 
procedure involving the AM-VNAR1 and AC-VNAR2 vNAR-functionalized magnetic beads should conducted. 
To generate a mixture of antibodies comprising various combinations of heavy and light chains, we co-transfected 
the heavy and light chains of cetuximab and matuzumab in HEK293 cells and harvested the supernatant after 
five days of production. A fraction of the concentrated supernatant was diluted in PBS (1:1) before it was added 
to the AM-VNAR1-coated magnetic beads. The co-transfection of all four chains results in the generation of 
overall 10 different antibody constructs (Fig. 6a)12. Since the identified anti-idiotypic vNARs do not interact with 
Figure 4. Assessment of paratope-specificity of anti-idiotypic vNAR-Fc variants using Bio-Layer 
Interferometry. Cetuximab, matuzumab or mispaired variants combining a matuzumab heavy chain with a 
cetuximab light chain and vice versa were immobilized on sensortips. After a baseline measurement in kinetics 
buffer, association of each anti-idiotypic vNAR-Fc was performed at a concentration of 100 nM. Subsequently, a 
dissociation step was carried out in kinetics buffer.
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Figure 5. Anti-idiotypic vNAR-functionalized magnetic beads can selectively enrich cetuximab or matuzumab 
from 5% mouse serum. Streptavidin magnetic beads were coated with biotinylated AC-VNAR2 and AM-
VNAR1, respectively. Subsequently, the functionalized beads were incubated with a mixture of 10 µg cetuximab 
or matuzumab (440 nM) in the presence of 5% mouse serum. The sample prior to application to the beads 
(lane 1), the flowthrough (lane 2), the first out of four washes (lane 3) and the eluate (lane 4) were subsequently 
applied to an SDS-PAGE and blotted onto a nitrocellulose membrane. The membrane was stained with Ponceau 
S in order to visualize the total amount of protein that was transferred from the SDS gel (upper and lower left). 
Afterwards, the membrane was destained and the human Fc region of cetuximab and matuzumab was detected 
using an anti-human Fc antibody that was conjugated to alkaline phosphatase (upper and lower right). It is 
observable, that the detected bands in the eluates correspond to enriched cetuximab or matuzumab heavy 
chains, respectively.
Figure 6. Immunoaffinity enrichment of bispecific cetuximab × matuzumab antibody constructs. (a) 
Schematic depiction of the enrichment procedure involving vNAR-functionalized magnetic beads. The 
heterogeneous antibody mixture that is obtained after co-transfection of heavy and light chains of matuzumab 
and cetuximab can potentially comprise ten different constructs. After the first purification step, only variants 
with an intact matuzumab paratope should be eluted, reducing the number of available molecules to four. 
After the last purification step, only the bispecific antibody variant is enriched since the anti-idiotypic vNARs 
presented in this investigation exclusively interact with correctly assembled paratopes. (b) The two-step 
purification process was illustrated on a SDS-PAGE. Since there is a slight difference in weight between the 
cetuximab and matuzumab light chains, the intensity of each light chain band can be utilized as a guideline 
during purification. The last lane containing the final eluate exhibits equal intensities for both light chains, 
underpinning a successful enrichment. For reasons of clarity, the supernatant as well as the flowthrough after 
incubation with the anti-matuzumab beads were purified using Protein A magnetic beads.
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mispaired heavy and light chains, the first purification step should reduce the number of available antibody vari-
ants to four (Fig. 6a). In that manner, only antibodies comprising an intact matuzumab paratope should interact 
with the beads. Subsequently, the eluate from the AM-VNAR1-functionalized beads was buffer-exchanged to 
PBS and added to AC-VNAR2-coated magnetic beads. During this second purification step, only the bispecific 
antibody comprising an intact cetuximab and an intact matuzumab paratope should interact with the matrix. The 
purification process was monitored on an SDS-PAGE (Fig. 6b). Due to the slight difference in weight of the matu-
zumab and cetuximab light chains, the intensity of each light chain band can be utilized as a guideline during the 
step-wise purification. Whereas the first eluate after incubation with AM-VNAR1-coated beads contains a higher 
amount of matuzumab light chains, the second eluate reveals the presence of equal amounts of both light chains. 
This indicates that the two-step capturing procedure succeeded and that only the bispecific antibody variant is 
obtained after the final elution step.
Discussion
In the present investigation, we added shark-derived IgNAR variable domains to the list of binders that can be 
engineered towards anti-idiotypic binding of monoclonal antibodies recognizing discontinuous epitopes. Our 
approach includes CDR3-randomized, semi-synthetic libraries and therefore omits the need for animal immu-
nizations. In addition, our libraries are thoroughly sampled using yeast surface display. To our knowledge, this is 
the first time that yeast display was utilized as a high-throughput platform for the identification of anti-idiotypic 
binders42. Subsequently, we could demonstrate that reformatted and bivalent vNAR single clones, comprising 
bivalent affinities in the pico- to nanomolar range for matuzumab or cetuximab, were highly specific for their 
cognate antigen, even in the presence of human or mouse serum. Despite the fact that no selection pressure was 
applied during fluorescence-activated cell sorting, all binders solely engaged the antigen-binding region of the 
respective target monoclonal antibody, while no binders against the constant regions were obtained. Moreover, 
binding required the correct pairing of cetuximab or matuzumab heavy and light chain. Mispaired variants 
combining the cetuximab heavy with a matuzumab light chain and vice versa were not recognized. Although 
no co-crystal structures of these anti-idiotypic vNARs in complex with their target antibodies are available, we 
propose that these domains might be predisposed for the engagement of antibody variable regions. A possi-
ble explanation for the isolation of vNAR variants which almost exclusively interact with the antibody variable 
regions could be the hydrophobic nature of the paratope. It is well-known that antibodies often comprise aromatic 
residues such as Phe, Tyr and Trp in their CDR binding sites43. Such residues could represent favorable interaction 
sites for vNAR domains. Indeed, the CDR3 loops of the isolated anti-cetuximab and anti-matuzumab vNARs 
comprise a relatively high number of aromatic histidine residues, which can be attributed to the initial library 
design (Supplementary Fig. S1). These histidine residues could interact with aromatic CDR residues of monoclo-
nal antibodies via π-π stacking or cationic π-interactions44, 45, delivering an explanation for the observation that 
only vNAR domains targeting the paratope rather than the antibody constant regions are identified. However, it 
needs to be scrutinized more meticulously whether these effects are also observed when non-histidine-enriched 
libraries are being employed.
It is also tempting to speculate that anti-idiotypic vNARs are structurally able to engage interspaces at the 
interaction site of heavy and light chains of a monoclonal antibody, which could be attributed to their elongated 
CDR3 binding sites29. Although antibody paratopes exhibit a rather flat structural architecture, vNARs could 
be able to penetrate this region with high specificity, as indicated by the results presented in this investigation 
and also previous results published by Simmons and coworkers42. Since our investigations focused on mono-
clonal antibody targets that engage a conformational rather than a linear epitope on their respective antigen, it 
is fairly difficult to identify sequence similarities between EGFR and the anti-idiotypic vNARs presented in this 
work. We exemplarily proposed a structural model for the anti-matuzumab vNARs using molecular modelling 
in order to explain why these domains almost exclusively recognize the antibody paratope. As depicted in Fig. 7, 
the CDR3 binding sites of AM-VNAR1 and AM-VNAR2 potentially adopt a conformation similar to that of 
the matuzumab-engaging loop of EGFR domain III (Fig. 7A,B and C). Notably, a loop-helix motif proposed 
for the CDR3 binding site of both vNAR domains seems to correlate with a related structure identified in the 
EGFR backbone (Fig. 7D). In case of AM-VNAR1, several amino acid residues of the CDR3 binding site over-
lap with residues of EGFR that possess similar interaction abilities. These residues include Lys463, Gly461 and 
Ser460 of EGFR which overlap with residues Arg88, Ala90 and His91 of AM-VNAR1, respectively (Fig. 7E). For 
AM-VNAR2, the modelled binding poses were not as conclusive as for AM-VNAR1. However, the observed sim-
ilarity between amino acids residues Lys463 of EGFR and Arg88 were likewise observable (Fig. 7F). Additionally, 
the hydrogen bond donor as well as acceptor properties displayed by Ser460 of EGFR could functionally be mim-
icked by residues Tyr90 or His92 of AM-VNAR2. These in silico modelling experiments could at least provide a 
partial explanation for the observation that our semi-synthetic libraries exclusively yield anti-idiotypic binders.
Anti-idiotypic binders can generally be employed for a wide range of different applications, ranging from the 
characterization of therapeutic antibodies to the profiling of auto-antibodies in patients suffering from autoim-
mune diseases21. Anti-idiotypic binders which represent an ‘internal image’ of the antigen of the respective target 
antibody have also been employed as cancer vaccines, thereby circumventing the problem of immune tolerance 
that is associated with most tumour-associated antigens13, 14. Anti-idiotypic entities can bypass this problem upon 
eliciting an immune response that is directed towards their own paratope. These anti-anti-idiotypic antibodies 
in turn often exhibit similar properties to the actual therapeutic antibody that has been utilized for the genera-
tion of anti-idiotypic candidates. Thus, not only antibodies towards tumour-associated proteins but also towards 
non-proteic antigens such as carbohydrates have efficiently been utilized for their development and, towards this 
end, for the immunization and vaccination of animals13, 46, 47.
The identification of anti-idiotypic binders which are able to specifically target cetuximab and matuzumab 
has already been described by Hartmann and colleagues in 201015. Their experiments initially encompassed 
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phage display selections of randomized peptide libraries that should engage either cetuximab or matuzumab. 
However, the identified peptide candidates revealed cross-reactivity and were not able to distinguish between the 
two therapeutic antibodies. Importantly, no cross-reactivity was observed for the anti-idiotypic vNARs identified 
in our investigation. Interestingly, the peptides identified from both phage screening campaigns conducted by 
Hartmann and colleagues possessed two common amino acid motifs, namely KTL and YPLG15. When look-
ing at the sequences from our anti-idiotypic vNARs, we were able to identify a motif similar to YPLG (YGLG, 
YVLG and YALG) in the CDR1 binding sites (Supplementary Fig. S1). The tyrosine residue has been intro-
duced manually prior to randomization of the CDR3 loop and library generation since bamboo shark-derived 
vNAR sequences naturally comprise a cysteine residue at this position31. Upon mutating this residue to tyrosine 
and excluding cysteine residues during the CDR3-randomization process, we wanted to circumvent the forma-
tion of any disulfide bonds between CDR1 and CDR331. Although these YXLG motifs were present in both sets 
of anti-idiotypic binders, they do not seem to affect their specificity as no cross-reactivity for the matuzumab 
binders towards cetuximab and vice versa was observable. However, since no crystal structures of anti-idiotypic 
vNARs in complex with their cognate target antibody are available, we can only speculate about the general 
contribution of the non-randomized CDR1 binding site to the actual protein-protein interaction. We also iden-
tified anti-idiotypic vNARs targeting other monoclonal antibodies that do not naturally engage EGFR (data not 
shown) and those sequences likewise comprised a YXLG sequence in CDR1. These antibodies were not able 
to interact with either cetuximab or matuzumab, leading to the conclusion that this amino acid motif is not 
associated with target specificity in our case. Likewise, Simmons and coworkers identified anti-idiotypic vNARs 
with no obvious sequence homology to the three amino acid minimal motif recognized by their target antibody, 
suggesting the formation of a similar but discontinuous motif caused by contributions from CDR142. Notably, our 
anti-cetuximab vNARs also did not comprise any sequence homology to the anti-cetuximab peptides published 
by Riemer and colleagues48.
We further demonstrated that anti-idiotypic vNARs might be suitable for the immunoaffinity enrichment 
of cetuximab × matuzumab bispecific antibodies. Analogous to the approach recently published by Godar and 
coworkers, anti-idiotypic entities which are specific for intact antibody paratopes can be utilized for the capture of 
bispecific antibodies from complex mixtures12. Indeed, we could show that after a two-step purification procedure 
Figure 7. In silico modelling of binding poses for anti-matuzumab vNARs AM-VNAR1 and AM-VNAR2. (A) 
Matuzumab (green) in complex with domain III of the extracellular portion of EGFR (grey). The corresponding 
loop region that mediates the interaction with matuzumab is depicted in black. Structures were modelled 
from PDB identifier 3C09. (B) and (C) Modelled binding poses for AM-VNAR1 and AM-VNAR2 (blue), 
respectively, in complex with matuzumab. The CDR3 binding site is depicted in black. VNAR X-ray structures 
were selected based on sequence similarity and sequence coverage (PDB identifier 2I26). (D) Close-up view 
of the matuzumab-engaging loop of EGFR domain III. (E) and (F) Structural overlay and close-up view of 
AM-VNAR1 (E) and AM-VNAR2 (F, depicted in blue) as well as the respective EGFR loop (black) in complex 
with matuzumab. All homology models were built using Molecular Operating Environment (MOE, Chemical 
Computing Group).
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using anti-idiotypic vNAR-functionalized magnetic beads, equal intensities for the cetuximab and matuzumab 
light chains were observable on the corresponding SDS-PAGE. As only small amounts of functionalized beads 
were utilized for the proof-of-concept purification, the amount of the bispecific construct that was obtained after 
the second elution step was quite low. In addition, both parts of the cetuximab × matuzumab bispecific antibody 
engage EGFR, which makes it rather difficult to precisely prove the bispecific nature of the purified construct. 
Nevertheless, our anti-idiotypic binders verifiably only engage correctly assembled heavy/light chain combina-
tions and a similar light chain segregation pattern during purification has also been observed by Godar and 
colleagues, underpinning a successful enrichment.
In conclusion, highly specific anti-idiotypic vNAR variants can easily be identified from semi-synthetic librar-
ies. They were characterized and produced in less than three months, enabling a fast and customizable process 
for each individual target antibody. This generic yeast display and library screening approach obviates animal 
immunization and delivers binding proteins for monoclonal antibodies with ramifications for applications in 
antibody analytics and purification.
Materials and Methods
Yeast strains, media and reagents. The Saccharomyces cerevisiae strain EBY100 was utilized for yeast sur-
face display33. YPD medium was composed of 20 g/L tryptone, 20 g/L dextrose and 10 g/L yeast extract. SD-CAA 
medium was prepared using 6.8 g/L yeast nitrogen base without amino acids but supplemented with ammonium 
sulphate, 5 g/L Bacto Casamino Acids, 20 g/L dextrose, 8.6 g/L NaH2PO4 × H2O, and 5.4 g/L Na2HPO4. SG-CAA 
medium was prepared similarly except for the substitution of dextrose sugar with galactose. Phosphate-buffered 
saline (PBS) contained 8.1 g/L NaCl, 0.75 g/L KCl, 1.13 g/L Na2HPO4 and 0.27 g/L KH2PO4. Cetuximab and matu-
zumab antibodies were kindly provided by Merck.
Yeast library construction. The PCR-amplified vNAR products from overall three non-immunized bam-
boo sharks served as template for a consecutive three-step PCR. It is important to notice that the vNAR templates 
comprised a cysteine to tyrosine mutation in CDR1, which was introduced during the first PCR reaction. A 
detailed scheme can be found in a previously published paper from our group31. During the second PCR, rand-
omization of either 12, 14, 16 or 18 amino acids in the CDR3 regions was carried out using a pre-assembled trinu-
cleotide mixture (EllaBiotech), wherein each amino acid-encoding trimer except the one for cysteine was utilized. 
The trimer mixtures were biased towards the introduction of a higher percentage of histidine. As such, 2–4 his-
tidine incorporations per loop (depending on its length) should be incorporated, allowing for the selection of 
potentially pH-sensitive variants32. During the third PCR, homologous sequences for gap repair cloning in yeast 
with the linearized pCT vector were attached33. The respective PCR products were purified using the Wizard® SV 
Gel and PCR Clean-up System (Promega) according to the manufacturer’s protocol. The pCT plasmid used for 
gap repair cloning and surface presentation of vNAR variants was digested with the restriction enzymes NheI-HF 
and BamHI-HF and purified using the Wizard® SV Gel and PCR Clean-up System (Promega). For each electro-
poration reaction, 1.5 µg of digested pCT plasmid were combined with 4.5 µg of insert. Overall, 10 transformation 
reactions per library were performed. Dilution plating was carried out in order to determine the library size after 
three days. Yeast cells were transferred to SD-CAA medium and grown for two days at 30 °C39.
Yeast library screening. Prior to library screenings, plasmid DNA from positive clones was isolated and 
sent out for sequence analysis. Library screening for the isolation of anti-idiotypic vNAR variants was performed 
on a BD InfluxTM cell sorter and analyzed via BD FACSTM Sortware v1.0. For each of the two first sorting rounds, 
8 × 108 cells were labelled with either 1 µM cetuximab or matuzumab. The detection of vNAR-displaying cells 
exhibiting target binding was generally carried out using an anti-c-myc-biotin antibody (mouse, monoclonal, 
Miltenyi Biotec), an anti-human IgG antibody (Fc gamma-specific, goat, monoclonal, diluted 1:100, affymetrix 
eBioscience) or an anti-human Fc specific Fab fragment that was conjugated to Alexa Fluor® 488 (diluted 1:200 in 
PBS, goat, Jackson ImmunoResearch) as well as either streptavidin conjugated to allophycocyanin (diluted 1:50 
in PBS pH 7.4, affymetrix eBioscience) or R-phycoerythrin (diluted 1:100 in PBS, Life Technologies). Incubation 
steps were performed at room temperature for 1 h (cetuximab and matuzumab) or 20 minutes on ice (secondary 
labelling reagents), respectively. The following rounds were performed upon staining at least ten times the num-
ber of yeast cells sorted in the previous round in order to ensure adequate library coverage. Secondary labelling 
reagents were alternated in order to circumvent the enrichment of vNARs interacting with these reagents.
Reformatting and recombinant expression of anti-idiotypic vNARs as Fc fusions. Reformatting 
of the identified anti-idiotypic vNARs was accomplished upon genetically fusing them to an IgG1 Fc 
region encoded in the mammalian expression vector pEXPR-IBA42. VNAR variants were connected with the 
Fc region via a H20 hinge linker. Notably, the Fc sequence contained an Asn297Ala mutation in order to pre-
vent glycosylation of the resulting fusion protein. Ligated constructs were sequence-verified and expressed in 
Expi293FTM cells subsequent to ExpiFectamineTM-mediated transient transfection according to the manufac-
turer’s instructions (Life Technologies). Culture supernatants were harvested, sterile-filtered (0.22 µm Stericup 
filter, EMD Millipore) and purified using ProSep® Protein A columns (EMD Millipore). Buffer exchange was 
performed with 10 kDa Amicon Ultra filter units (EMD Millipore). Analytical size exclusion chromatography was 
carried out using a TSKgel SuperSW3000 column (4.6 × 300 mm, Tosoh) at a flow rate of 0.35 mL/min.
Specificity and serum ELISA assays. For specificity ELISA assays, anti-idiotypic vNARs were coated onto 
Nunc MaxiSorp® plates at 1–3 µg/mL at 4 °C over night. Subsequently, plates were blocked using 3% bovine serum 
albumin (BSA) in PBS for at least 2 h at room temperature. Plates were washed thrice with PBS 0.1% Tween-20. 
Incubations using cetuximab, matuzumab or other unrelated antibodies and the IgG mixture Gamunex® (Grifols 
Deutschland GmbH) were carried out for 1 h at room temperature and upon employing 500 nM or 1000 nM 
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of the respective antibodies in PBS 1% BSA. In case of AM-VNAR1 and AM-VNAR2, incubations were con-
ducted with biotinylated antibodies. Biotinylation was carried out using a two-fold molar excess of EZ-Link 
Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific) for 30 minutes at room temperature. Biotinylated antibodies 
were subsequently purified using Protein Desalting Spin Columns (MWCO 3 kDa, Thermo Fisher Scientific). 
Unrelated antibodies were either kindly provided by Merck KGaA, Darmstadt (Adalimumab, anti-cMET IgG and 
isotype control), purchased from Sigma-Aldrich (SILuTM Lite SigmaMab) or recombinantly expressed in HEK293 
cells in-house (Trastuzumab). After washing the plates thrice with PBS 0.1% Tween-20, captured antibodies were 
labelled using an anti-Fab specific antibody conjugated to horseradish peroxidase (HRP, diluted 1:5000 in PBS 
1% BSA, Sigma-Aldrich) or an Extravidin horseradish peroxidase conjugate (diluted 1:5000 in PBS 1% BSA, 
Sigma-Aldrich). Incubations were performed at room temperature for 30 minutes. After washing the plates thrice 
with PBS 0.1% Tween-20, a 1:1 mixture of TMB One Solution (Promega) and water was added to each well. 
Ultimately, reactions were stopped using 0.2 M HCl and plates were read on a Tecan Infinite F200 plate reader.
Serum ELISA assays were performed likewise. Biotinylated cetuximab and matuzumab were added to 
vNAR-Fc coated plates at a concentration of 500 nM or 1000 nM in the presence of either 10% human serum 
(Merck Millipore) or PBS 1% BSA and were serially diluted by a factor of 2. Captured antibodies were detected 
using Extravidin-HRP.
Capturing assays using vNAR-functionalized magnetic beads. VNAR-Fc fusion proteins 
AC-VNAR2 and AM-VNAR1 were biotinylated using a four-fold molar excess of EZ-Link Sulfo-NHS-LC-Biotin 
(Thermo Fisher Scientific) for 30 minutes at room temperature. Biotinylated antibodies were subsequently puri-
fied using Protein Desalting Spin Columns (MWCO 3 kDa, Thermo Fisher Scientific). Streptavidin magnetic 
beads were purchased from GE Healthcare (Streptavidin Mag Sepharose) and functionalized with biotinylated 
vNARs according to the manufacturer’s instructions. After coupling, magnetic beads were stripped using 0.1 M 
glycine buffer at pH 3. Overall, about 77 µg of AC-VNAR2-Fc and 60 µg of AM-VNAR1-Fc were coupled to 50 µL 
of bead slurry. For capturing experiments, a 440 nM solution (10 µg of each antibody in total) of either cetux-
imab or matuzumab with 5% mouse serum (kindly provided by Merck) in PBS was added to AC-VNAR2- or 
AM-VNAR1-coated beads, respectively. After incubation at 4 °C for 30–60 minutes, the beads were washed at 
least 4 times using 500 µL PBS. Elution was carried out using 50 µL 0.1 M glycine buffer at pH 3. The eluate was 
subsequently transferred into a new tube containing 1 M Tris buffer at pH 9.
After running the collected samples on a 15% SDS-PAGE, proteins were blotted onto a nitrocellulose mem-
brane (AmershamTM ProtranTM 0.45 µm NC, GE Healthcare Life Science). Blotted membranes were subsequently 
stained using Ponceau S solution (0.1% (w/v), 5% acetic acid; Sigma-Aldrich). Destaining was conducted using 
PBS 0.1% Tween-20. After a blocking step with 3% milk powder for at least 2 hours, the membrane was washed 
several times with PBS and was subsequently incubated with an anti-human Fc specific antibody conjugated to 
alkaline phosphatase (diluted 1:5000 in PBS with 1.5% milk powder, Sigma-Aldrich). Afterwards, the membrane 
was consecutively washed with PBS, water and alkaline phosphatase buffer (100 mM NaCl, 50 mM MgCl2 × 6 
H2O, 100 mM Tris, pH 9.1). Bands were developed using 12 µl of a 75 mg/mL solution of NBT in 70% DMF and 
75 µL of a 50 mg/mL solution of BCIP in 100% DMF.
Production and capturing of bispecific cetuximab × matuzumab antibodies. Initially, HEK293 
cells were transfected with four plasmids encoding for the matuzumab heavy and light chains and cetuximab 
heavy and light chains. After five days of production, the culture supernatant was harvested and concentrated 
using a 10 kDa Amicon Ultra filter unit (EMD Millipore). The concentrated supernatant was then subjected to 
incubations using AM-VNAR1-functionalized magnetic beads according to the procedure described for the cap-
turing assays in mouse serum. The eluates after the elution step were buffer-exchanged against PBS using Protein 
Desalting Spin colums (Thermo Fisher Scientific) and then applied to AC-VNAR2-coated beads. Incubation 
and elution was carried out as described above. The final eluates were subsequently concentrated using 10 kDa 
Amicon Ultra filter unit (EMD Millipore). After separation of the collected samples on a 15% SDS-PAGE, a silver 
staining was performed.
Bio-Layer Interferometry measurements. Determination of binding kinetics was performed on 
an Octet® RED96 system (fortéBio) at 30 °C, orbital sensor agitation at 1000 rpm and in 200 µL volume. 
Anti-Fab-CH1 or streptavidin sensor tips were pre-wet in PBS for 10 minutes. Subsequently, matuzumab or 
cetuximab were loaded onto the tips at a concentration of 5–10 µg/mL for 300 s. Afterwards, a baseline measure-
ment was done in kinetics buffer (PBS, 0.1% BSA, 0.02% Tween-20) for 120 s. Association was performed using 
decreasing concentrations of anti-idiotypic vNAR-Fc fusion proteins for 300 s. Dissociation was performed in 
kinetics buffer for 600 s (AC-VNARs) or 900 s (AM-VNARs). Sensorgrams were fitted using a 1:1 Langmuir bind-
ing model (Analysis Software version 9.1) after subtraction of control curve date (without ligand).
Idiotope binnings were carried out upon immobilizing cetuximab, matuzumab, matuzumab HC/cetuximab 
LC and cetuximab HC/matuzumab LC on streptavidin sensortips for 300 s. After a baseline measurement in 
kinetics buffer for 120 s, association using 100 nM of each anti-idiotypic vNAR was carried out for 300 s, followed 
by a dissociation step in kinetics buffer for 600 s.
In silico modelling of binding poses. Binding poses of AM-VNAR1 and AM-VNAR2 were modelled 
based on the co-crystal structure of matuzumab and EGFR (PDB-ID: 3C09). To this end, a vNAR X-ray structure 
was selected based on sequence similarity and sequence coverage. PDB entry 2I26 was identified as a suitable 
scaffold for generating homology models of both matuzumab binders (AM-VNAR1: similarity 69%, gaps 0%; 
AM-VNAR2: similarity 67%, gaps 4%; data accessed via NCBI protein BLAST). Homology models were built 
using Molecular Operating Environment (MOE, Chemical Computing Group: Molecular Operating Environment 
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(MOE), 2015; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, 
H3A 2R7, 2017.). The standard settings and AMBER10:EHT as force field with the R-field solvation model 
were employed. The main interacting loop of EGFR (aa447–468) showed significant structural similarity to the 
CDR3 loops observed in our homology models of AM-VNAR1 and AM-VNAR2. Hence, matuzumab binders 
were aligned to this EGFR region. Resulting poses were energy-minimized after repacking of CDR3 amino acid 
side chains in the matuzumab environment. Both steps were conducted as standard operations in MOE using 
AMBER10:EHT and the R-field solvation model.
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